RISEDRONATE SODIUM HEMI-PENTAHYDRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C7H10NO7P2.2Na.5H2O
Molecular Weight	700.2646
Optical Activity	NONE
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of RISEDRONATE SODIUM HEMI-PENTAHYDRATE

Structure Search

SMILES

O.O.O.O.O.[Na+].[Na+].OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)([O-])=O.OC(CC2=CN=CC=C2)(P(O)(O)=O)P(O)([O-])=O

InChI

InChIKey=HYFDYHPNTXOPPO-UHFFFAOYSA-L

InChI=1S/2C7H11NO7P2.2Na.5H2O/c2*9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;;;;;;;/h2*1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);;;5*1H2/q;;2*+1;;;;;/p-2

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/risedronate.html http://www.wikidoc.org/index.php/Risedronate http://www.rxlist.com/actonel-drug.htm

Risedronic acid is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. It is FDA approved for the treatment of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis and Paget’s disease. Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of Risedronic acid. Common adverse reactions include rash, abdominal pain, constipation, diarrhea, indigestion, nausea, backache, urinary tract infectious disease and influenza-like illness.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Hydroxyapatite crystals 4 Target ID: Hydroxyapatite crystals Sources: https://www.ncbi.nlm.nih.gov/pubmed/25568655	Binding Agent 1064
Farnesyl diphosphate synthase 28 Target ID: CHEMBL1782 Sources: http://www.drugbank.ca/drugs/DB00884 \| https://www.ncbi.nlm.nih.gov/pubmed/25568655	Inhibitor 8297		3.9 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Postmenopausal osteoporosis 59 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf	Primary	Approved 8429	ACTONEL Approved Use ACTONEL is indicated for the treatment and prevention of osteoporosis and Paget’s disease of bone in men and women. Launch Date 1998
Glucocorticoid-induced osteoporosis 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf	Primary	Approved 8429	ACTONEL Approved Use ACTONEL is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of ≥ 7.5 mg prednisone or equivalent) for chronic diseases. Launch Date 1998
Paget’s disease of bone 12 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf	Primary	Approved 8429	ACTONEL Approved Use ACTONEL is indicated for treatment of Paget’s disease of bone in men and women. Launch Date 1998
Increase bone mass in men with osteoporosis 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf	Primary	Approved 8429	ACTONEL Approved Use ACTONEL is indicated for treatment to increase bone mass in men with osteoporosis. Launch Date 1998

C_max

Value	Dose	Co-administered	Analyte	Population
2.05 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/14999521	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		RISEDRONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
6.49 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/14999521	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		RISEDRONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.61 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/14999521	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		RISEDRONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18038273 Page: p.362	unhealthy, 41.6±15.7 n = 60 Health Status: unhealthy Condition: Glucocorticoid-induced bone mineral density loss prevention Age Group: 41.6±15.7 Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/18038273 Page: p.362	Disc. AE: Skin rash, Gastrointestinal upset... AEs leading to discontinuation/dose reduction: Skin rash (1.7%) Gastrointestinal upset (1.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/18038273 Page: p.362
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9	unhealthy, 50 - 86 n = 613 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 86 Sex: F Population Size: 613 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9	Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9	unhealthy, 50 - 86 n = 616 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 86 Sex: F Population Size: 616 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9	Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9
75 mg 1 times / day multiple, oral Recommended Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9	unhealthy, 50 - 86 n = 616 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 86 Sex: F Population Size: 616 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9	Disc. AE: Vomiting, Diarrhea... AEs leading to discontinuation/dose reduction: Vomiting (1%) Diarrhea (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9
150 mg 1 times / month multiple, oral Recommended Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10	unhealthy, 50 - 88 n = 650 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 88 Sex: F Population Size: 650 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10	Disc. AE: Abdominal pain upper, Diarrhea... AEs leading to discontinuation/dose reduction: Abdominal pain upper (2.5%) Diarrhea (0.8%) Vomiting (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10	unhealthy, 50 - 88 n = 642 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 88 Sex: F Population Size: 642 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10	Disc. AE: Abdominal pain upper, Vomiting... AEs leading to discontinuation/dose reduction: Abdominal pain upper (1.4%) Vomiting (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10

AEs

AE	Significance	Dose	Population
Gastrointestinal upset	1.7% Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18038273 Page: p.362	unhealthy, 41.6±15.7 n = 60 Health Status: unhealthy Condition: Glucocorticoid-induced bone mineral density loss prevention Age Group: 41.6±15.7 Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/18038273 Page: p.362
Skin rash	1.7% Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18038273 Page: p.362	unhealthy, 41.6±15.7 n = 60 Health Status: unhealthy Condition: Glucocorticoid-induced bone mineral density loss prevention Age Group: 41.6±15.7 Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/18038273 Page: p.362
Diarrhea	0.3% Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9	unhealthy, 50 - 86 n = 613 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 86 Sex: F Population Size: 613 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9
Vomiting	0.2% Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9	unhealthy, 50 - 86 n = 616 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 86 Sex: F Population Size: 616 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9
Diarrhea	1% Disc. AE	75 mg 1 times / day multiple, oral Recommended Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9	unhealthy, 50 - 86 n = 616 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 86 Sex: F Population Size: 616 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9
Vomiting	1% Disc. AE	75 mg 1 times / day multiple, oral Recommended Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9	unhealthy, 50 - 86 n = 616 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 86 Sex: F Population Size: 616 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.9
Vomiting	0.3% Disc. AE	150 mg 1 times / month multiple, oral Recommended Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10	unhealthy, 50 - 88 n = 650 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 88 Sex: F Population Size: 650 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10
Diarrhea	0.8% Disc. AE	150 mg 1 times / month multiple, oral Recommended Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10	unhealthy, 50 - 88 n = 650 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 88 Sex: F Population Size: 650 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10
Abdominal pain upper	2.5% Disc. AE	150 mg 1 times / month multiple, oral Recommended Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10	unhealthy, 50 - 88 n = 650 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 88 Sex: F Population Size: 650 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10
Vomiting	0.3% Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10	unhealthy, 50 - 88 n = 642 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 88 Sex: F Population Size: 642 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10
Abdominal pain upper	1.4% Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10	unhealthy, 50 - 88 n = 642 Health Status: unhealthy Condition: Postmenopausal osteoporosis Age Group: 50 - 88 Sex: F Population Size: 642 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf Page: p.10

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY510605	https://www.001chemical.com/chem/1197-18-8
3B Scientific (Wuhan) Corp	3B3-004681	http://www.3bsc.com/index/pro_info.php?id=26567
AA Blocks	AA00HAKO	https://www.aablocks.com/goods/Goods/detail?id=AA00HAKO
AHH Chemical co.,ltd	MT-15499	http://www.ahhchemical.com/product/MT-15499.html
AK Scientific, Inc. (AKSCI)	2689AH	http://www.aksci.com/item_detail.php?cat=2689AH
AK Scientific, Inc. (AKSCI)	I802	http://www.aksci.com/item_detail.php?cat=I802
Aaron Chemicals	AR00HBCG	http://www.aaronchem.com/105462-24-6
Acadechem	ACDS-026260	http://www.acadechemical.com/product/100959
Achemo Scientific Limited	AC-15534	http://www.achemo.com/product_view.asp?ID=5424
Achemtek	0104-019190	http://www.achemtek.com/105462-24-6
Adooq BioScience	A11675	https://www.adooq.com/risedronic-acid-actonel.html
Ambeed	A471285	https://www.ambeed.com/products/105462-24-6.html
Angene	AGN-PC-04XTDK	http://www.angenechemical.com/productshow/AGN-PC-04XTDK.html
ApexBio Technology	B1826	http://www.apexbt.com/risedronate.html
AstaTech, Inc.	67956	http://www.astatechinc.com/CPSResult.php?CRNO=14010
Aurum Pharmatech LLC	M-1366	http://www.Aurumpharmatech.com/Product/ProductDetails/M_1366
AvaChem Scientific	2610A	http://www.avachem.com/productSearch.asp?2610A
BLD Pharm	BD17422	http://www.bldpharm.com/products/105462-24-6.html
BioChemPartner	BCP13805	http://www.biochempartner.com/105462-24-6-BCP13805
BioCrick	BCC4711	http://www.biocrick.com/Risedronate-BCC4711.html
Boerchem	BC206977	http://www.boerchem.com/?product_34916.html
CSNpharm	CSN12477	https://www.csnpharm.com/products/risedronate.html
Capot Chemical	14002	http://www.capotchem.com/en/14002.htm
Capot Chemical	PubChem14002	http://www.capotchem.com/en/14002.htm
Chem Scene	CS-1964	http://www.chemscene.com/105462-24-6.html
ChemMol	30103518	http://www.chemmol.com/chemmol/30103518.html
ChemMol	44002664	http://www.chemmol.com/chemmol/44002664.html
ChemMol	49408876	http://www.chemmol.com/chemmol/49408876.html
Chemenu	CM110535	http://www.chemenu.com/products/CM110535
Chemspace	CSSB00000692965	https://chem-space.com/CSSB00000692965
Clearsynth	CS-O-11736	https://www.clearsynth.com/en/CSO11736.html
DC Chemicals	DCAPI1012	http://www.dcchemicals.com//product_show-Risedronic_acid_Actonel_.html
Enamine	Z2684418685	https://www.enaminestore.com/catalog/Z2684418685
Finetech	FT-0642593	http://www.finetechnology-ind.com/prod/detail/pub/105462-24-6.html
Glentham Life Sciences	GP6400	http://www.glentham.com/products/product/GP6400/
Hairui	HR124405	http://www.hairuichem.com/en/product/1197-18-8.html
Huateng Pharma	F80017483	http://en.huatengsci.com/product/Risedronic-acid-monohydrate.html
LGC Standards	MM0777.09-0025	https://www.lgcstandards.com/US/en/p/MM0777.09-0025
MedChem Express	HY-B0148	https://www.medchemexpress.com/Risedronic-acid.html
Molcore	MC510605	https://www.molcore.com/product/1197-18-8
MuseChem	A000751	https://www.musechem.com/product/A000751.html
OChem	3875	http://www.ocheminc.com/index.php?act=psearch&pid=462R246
Selleck Chemicals	S1874	http://www.selleckchem.com/products/risedronic-acid-actonel.html
Sinfoo Biotech	S010603	http://www.sinfoobiotech.com/product/1014001
Smolecule	S591430	https://www.smolecule.com/products/s591430
THE BioTek	bt-311863	https://www.thebiotek.com/product/others/bt-311863
Yuhao Chemical	XJ6805	http://www.chemyuhao.com/105462-24-6.html
abcr GmbH	AB504521	http://www.abcr.com/shop/en/AB504521

PubMed

Title	Date	PubMed
Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.	2001 Apr	11354395
Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature.	2001 Aug	11496161
Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials.	2001 Dec	11846337
Review of risedronate in the treatment of osteoporosis.	2001 Dec	11825332
Anabolic agents for treating postmenopausal osteoporosis.	2001 Dec	11809001
[Therapy of osteoporosis. Risk factors alone are not an indication].	2001 Dec 6	11813710
Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation.	2001 Feb	11160853
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.	2001 Feb	11160603
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.	2001 Feb 1	11172164
Comparison insight dual X-ray absorptiometry (DXA), histomorphometry, ash weight, and morphometric indices for bone evaluation in an animal model (the orchidectomized rat) of male osteoporosis.	2001 Jan	12037621
[Fluorides and bisphosphonates in the treatment of osteoporosis].	2001 Jul	11515184
Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis.	2001 Jul	11485341
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].	2001 Jul 14	11484428
Re: Lanza et al.--Endoscopic comparison of alendronate and risedronate.	2001 Jun	11419858
Hip fractures: do preventive drugs work for all?	2001 Mar	11263091
Once-a-week alendronate (Fosamax).	2001 Mar 19	11257718
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.	2001 May	11344179
Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles.	2001 May	11344052
[Bisphosphonates in osteoporosis. Significantly reduces risk of fracture].	2001 May 3	11393183
The effect of risedronate on the risk of hip fracture in elderly women.	2001 May 31	11386284
The effect of risedronate on the risk of hip fracture in elderly women.	2001 May 31	11386283
A method to assess the proportion of treatment effect explained by a surrogate endpoint.	2001 Nov 15	11746311
Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.	2001 Oct	11595616
Risedronate: a new oral bisphosphonate.	2001 Sep	11589256
Bisphosphonates for osteoporosis.	2001 Sep	11586803
Pharmacologic therapy for the treatment and prevention of osteoporosis.	2001 Sep	11532658
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.	2001 Sep 1	11520816
Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates.	2002	11860614
[Osteoporosis - Evidence based therapy].	2002 Apr	11930292
Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.	2002 Feb	11844743
Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results.	2002 Jan	11829081
Activity of bisphosphonates against Trypanosoma brucei rhodesiense.	2002 Jul 4	12086478
Gateways to clinical trials.	2002 May	12092009
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.	2002 May 28	12054412
The potential of parathyroid hormone as a therapy for osteoporosis.	2002 May-Jun	12081255

Patents

Sample Use Guides

In Vivo Use Guide

Treatment of Postmenopausal Osteoporosis: 5 mg daily, 35 mg once-a-week, 75 mg two consecutive days each month, 150 mg once-a-month. Prevention of Postmenopausal Osteoporosis: 5 mg daily, 35 mg once-a-week. Men with Osteoporosis: 35 mg once-a-week. Glucocorticoid-Induced Osteoporosis: 5 mg daily. Paget’s Disease: 30 mg daily for 2 month.

Route of Administration: Oral

In Vitro Use Guide

The antimalarial activities of risedronate, one of the most potent bisphosphonates clinically used to treat bone resorption diseases, against blood stages of Plasmodium falciparum (50% inhibitory concentration [IC50] of 20.3±1.0 μM).

Name

Type

Language

RISEDRONATE SODIUM HEMI-PENTAHYDRATE

Common Name

English

SODIUM TRIHYDROGEN (1-HYDROXY-2-(3-PYRIDYL)ETHYLIDENE)DIPHOSPHONATE HEMI-PENTAHYDRATE

Common Name

English

RISEDRONATE SODIUM HEMIPENTAHYDRATE

Common Name

English

SODIUM RISEDRONATE HYDRATE [JAN]

Common Name

English

PHOSPHONIC ACID, P,P'-(1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS-, SODIUM SALT, HYDRATE (2:2:5)

Common Name

English

RISEDRONIC ACID MONOSODIUM SALT HEMIPENTAHYDRATE

Common Name

English

RISEDRONATE SODIUM 2.5-HYDRATE [EP MONOGRAPH]

Common Name

English

SODIUM RISEDRONATE HYDRATE

Common Name

English

Code System Code Type Description

DRUG BANK

DBSALT001515

Created by admin on Sat Dec 16 03:13:59 GMT 2023 , Edited by admin on Sat Dec 16 03:13:59 GMT 2023

PRIMARY

DAILYMED

HU2YAQ274O

Created by admin on Sat Dec 16 03:13:59 GMT 2023 , Edited by admin on Sat Dec 16 03:13:59 GMT 2023

PRIMARY

PUBCHEM

11954322

Created by admin on Sat Dec 16 03:13:59 GMT 2023 , Edited by admin on Sat Dec 16 03:13:59 GMT 2023

PRIMARY

SMS_ID

100000091405

Created by admin on Sat Dec 16 03:14:00 GMT 2023 , Edited by admin on Sat Dec 16 03:14:00 GMT 2023

PRIMARY

RXCUI

1356127

Created by admin on Sat Dec 16 03:14:00 GMT 2023 , Edited by admin on Sat Dec 16 03:14:00 GMT 2023

PRIMARY

RxNorm

CAS

329003-65-8

Created by admin on Sat Dec 16 03:13:59 GMT 2023 , Edited by admin on Sat Dec 16 03:13:59 GMT 2023

PRIMARY

EVMPD

SUB26270

Created by admin on Sat Dec 16 03:13:59 GMT 2023 , Edited by admin on Sat Dec 16 03:13:59 GMT 2023

PRIMARY

FDA UNII

HU2YAQ274O

Created by admin on Sat Dec 16 03:13:59 GMT 2023 , Edited by admin on Sat Dec 16 03:13:59 GMT 2023

PRIMARY

ACTIVE MOIETY


					KM2Z91756Z

RISEDRONIC ACID

SUBSTANCE RECORD


					HU2YAQ274O

RISEDRONATE SODIUM HEMI-PENTAHYDRATE

Details

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2